2. Academic Validation
  3. The identification of potent and selective imidazole-based inhibitors of B-Raf kinase

The identification of potent and selective imidazole-based inhibitors of B-Raf kinase

  • Bioorg Med Chem Lett. 2006 Jan 15;16(2):378-81. doi: 10.1016/j.bmcl.2005.09.072.
Andrew K Takle 1,  Murray J B Brown,  Susannah Davies,  David K Dean,  Gerraint Francis,  Alessandra Gaiba,  Alex W Hird,  Frank D King,  Peter J Lovell,  Antoinette Naylor,  Alastair D Reith,  Jon G Steadman,  David M Wilson
Affiliations

Affiliation

  • 1 Department of Medicinal Chemistry, Neurology and GI Centre of Excellence for Drug Discovery, GlaxoSmithKline Pharmaceuticals, New Frontiers Science Park, Third Avenue, Harlow, Essex CM19 5AW, UK. Andy.K.Takle@gsk.com
PMID: 16260133 DOI: 10.1016/j.bmcl.2005.09.072
Abstract

A novel triarylimidazole derivative, SB-590885 (33), bearing a 2,3-dihydro-1H-inden-1-one oxime substituent has been identified as a potent and extremely selective inhibitor of B-Raf kinase.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-10966
    99.77%, Raf Inhibitor
    Raf